Clarity Pharmaceuticals Stock Market Value
| CLRPF Stock | 2.23 0.05 2.29% |
| Symbol | Clarity |
Clarity Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Clarity Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Clarity Pharmaceuticals.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Clarity Pharmaceuticals on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Clarity Pharmaceuticals or generate 0.0% return on investment in Clarity Pharmaceuticals over 90 days.
Clarity Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Clarity Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Clarity Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 25.22 | |||
| Value At Risk | (7.39) | |||
| Potential Upside | 7.04 |
Clarity Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Clarity Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Clarity Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Clarity Pharmaceuticals historical prices to predict the future Clarity Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.42) | |||
| Total Risk Alpha | (0.65) | |||
| Treynor Ratio | (0.36) |
Clarity Pharmaceuticals February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.35) | |||
| Mean Deviation | 3.04 | |||
| Coefficient Of Variation | (1,234) | |||
| Standard Deviation | 4.55 | |||
| Variance | 20.73 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.42) | |||
| Total Risk Alpha | (0.65) | |||
| Treynor Ratio | (0.36) | |||
| Maximum Drawdown | 25.22 | |||
| Value At Risk | (7.39) | |||
| Potential Upside | 7.04 | |||
| Skewness | (0.44) | |||
| Kurtosis | 1.88 |
Clarity Pharmaceuticals Backtested Returns
Clarity Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.1, which signifies that the company had a -0.1 % return per unit of standard deviation over the last 3 months. Clarity Pharmaceuticals exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Clarity Pharmaceuticals' risk adjusted performance of (0.05), and Mean Deviation of 3.04 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.06, which signifies a somewhat significant risk relative to the market. Clarity Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Clarity Pharmaceuticals is expected to follow. At this point, Clarity Pharmaceuticals has a negative expected return of -0.47%. Please make sure to confirm Clarity Pharmaceuticals' treynor ratio, and the relationship between the standard deviation and kurtosis , to decide if Clarity Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.26 |
Weak reverse predictability
Clarity Pharmaceuticals has weak reverse predictability. Overlapping area represents the amount of predictability between Clarity Pharmaceuticals time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Clarity Pharmaceuticals price movement. The serial correlation of -0.26 indicates that nearly 26.0% of current Clarity Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.26 | |
| Spearman Rank Test | 0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |